Pharmacology Journal Enters Q1 Elite After Landing Major Citation Index Spot

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering drug delivery, pharmacokinetics and pharmaceutical technology, has confirmed that it is now abstracted and indexed in the Science Citation Index Expanded, the core citation database that underpins Thomson-era and now Clarivate’s Web of Science platform. The move, effective from 2021 coverage onward, places the journal inside the small circle of pharmaceutical science titles whose every published paper is tracked at the individual reference level, allowing citation counts to accumulate automatically across the global research literature. Alongside the indexing milestone, the journal reports a 2022 Journal Impact Factor of 5.5, a figure that ranks it 48th out of 278 titles in the Pharmacology and Pharmacy category and firmly within the top quartile, the Q1 band that many institutions treat as the benchmark for high-quality scholarly output.

To understand why this matters, it helps to unpack what abstracting and indexing actually involves. Abstracting services capture the summary, or abstract, of each article along with its metadata: authors, affiliations, keywords and journal details. Indexing goes a step further, embedding that metadata into structured databases that can be searched, cross-referenced and analyzed at scale. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is among the most selective of these databases. Journals are admitted only after an editorial evaluation that examines editorial rigor, peer-review integrity, the international diversity of authorship, regularity of publication and the citation behavior of the published content. Once a journal is accepted, every article it publishes is ingested, its reference list is parsed, and each cited reference is linked to the database’s network of scholarly records.

That reference linking is what makes citation metrics possible. When a paper published in the Journal of Pharmaceutical Investigation is cited by a researcher anywhere in the indexed literature, the event is recorded, timestamped and attributed. Aggregated over time, these events feed the Journal Impact Factor, a metric calculated annually in Clarivate’s Journal Citation Reports. The formula is deceptively simple: the 2022 impact factor counts citations made in 2022 to items the journal published in 2020 and 2021, divided by the number of citable items, typically articles and reviews, published in those same two years. A score of 5.5 therefore means that, on average, each citable paper from the journal’s 2020 and 2021 volumes was cited 5.5 times in the following year by the indexed literature.

The category ranking adds a second layer of interpretation. Pharmacology and Pharmacy is one of the largest and most competitive categories in the Journal Citation Reports, containing 278 journals that range from basic molecular pharmacology to clinical therapeutics and formulation science. Ranking 48th in that field places the journal in the 17th percentile, comfortably inside the Q1 quartile that spans the top 25 percent of titles. Quartile assignments matter in practical academic life: hiring committees, grant agencies and national evaluation systems in many countries use Q1 status as a shorthand for journal prestige, and some funding bodies explicitly require that publications appear in Q1 or Q2 journals to count toward a researcher’s track record.

For a journal focused on pharmaceutical investigation, the indexing milestone also changes how its content circulates. Articles in the Science Citation Index Expanded are surfaced through Web of Science searches used daily by millions of researchers, and the indexed metadata feeds into citation alerts, research profiles and institutional dashboards. Downstream services, including citation managers, discovery layers at university libraries and literature-screening tools used in drug-safety reviews, draw on the same structured records. In practical terms, a pharmacokinetics study or a novel drug-delivery paper published in the journal is now far more likely to be found, cited and built upon by teams working in formulation chemistry, clinical pharmacy and regulatory science around the world.

The timing is notable against the backdrop of a broader debate about how scientific quality should be measured. The impact factor, conceived in the 1960s as a tool for librarians deciding which journals to subscribe to, has become one of the most scrutinized numbers in science. Critics, including the signatories of the San Francisco Declaration on Research Assessment, argue that the metric is easily skewed by a small number of highly cited papers, that it differs across fields in ways that make cross-disciplinary comparisons misleading, and that it says nothing about the quality of any individual article. Defenders counter that, for all its flaws, the impact factor remains a transparent, reproducible and widely understood indicator of a journal’s average citation performance, and that quartile rankings within a single field, such as Pharmacology and Pharmacy, offer a fairer like-for-like comparison.

Clarivate itself has been evolving the ecosystem around these metrics. In recent years the Journal Citation Reports have added supplementary indicators, including the Journal Impact Factor percentile, the five-year impact factor and the Eigenfactor-style measures that weight citations by the prestige of the citing journal. The 2023 release extended impact factors to all journals in the Web of Science Core Collection, including those in the Emerging Sources Citation Index, a change that increased the number of titles receiving the metric from roughly 9,500 to more than 21,000. For newly indexed journals, this expansion means that citation performance is visible almost immediately after entry into the collection, rather than after the traditional multi-year waiting period, accelerating the feedback loop between publication and measurable scholarly impact.

Behind the headline numbers lies a labor-intensive editorial operation. Journals seeking Science Citation Index Expanded inclusion must demonstrate consistent publication schedules, robust peer-review processes, ethical publishing practices aligned with guidelines from the Committee on Publication Ethics, and content that is genuinely international in authorship and readership. Clarivate’s editorial development team also assesses whether the journal fills a distinctive niche relative to existing coverage, a criterion that rewards publications addressing specific research communities, such as pharmaceutical formulation, biopharmaceutics and translational drug research, rather than duplicating well-served areas. Once admitted, journals remain under continuous review, and titles whose quality or citation performance deteriorates can be flagged or delisted, a mechanism that has drawn increased attention as the publishing industry confronts paper mills and predatory outlets.

For researchers deciding where to submit their work, the combination of Q1 status and a 5.5 impact factor signals that the journal now competes directly with established titles in pharmaceutical science. Authors in drug delivery and pharmaceutical technology often weigh several factors beyond the impact factor: the speed of peer review, open-access options and licensing terms, the journal’s readership among industrial and regulatory scientists, and how quickly an accepted paper becomes visible in indexing services. Full indexing in the Science Citation Index Expanded addresses the visibility component decisively, since every accepted article enters the citation network from the point of indexing onward, accumulating the references that will determine future metric cycles.

The broader lesson from the journal’s trajectory is that scholarly visibility is built in layers: rigorous peer review attracts strong papers, strong papers attract citations, citations drive impact factors, and impact factors, in turn, attract more strong submissions. Indexing in the Science Citation Index Expanded is the infrastructure that makes this cycle measurable. As the 2023 and 2024 publication years accumulate citations, the journal’s position within the Pharmacology and Pharmacy rankings will be tested against 277 competitors, many of them far larger and longer-established. Whether it consolidates its Q1 standing or climbs higher, its entry into the citation mainstream marks the moment when its research output became fully countable in the quantitative machinery that increasingly shapes careers, funding decisions and the global flow of pharmaceutical science.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor ranking in pharmacology

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Web of Science, Journal Impact Factor, Clarivate, Q1 journal, Pharmacology and Pharmacy, citation analysis, abstracting and indexing, pharmaceutical science, research metrics, peer review